Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Morestril (often stylized as MORestril) is a multi-ingredient dietary supplement developed by Farmaceutici Damor as part of its Akademy Pharma initiative. It is specifically formulated to alleviate symptoms associated with menopause, such as hot flashes, night sweats, and mood swings, while also supporting bone health. The product typically contains a combination of phytoestrogens and botanical extracts, including soy isoflavones, *Cimicifuga racemosa* (black cohosh), and *Trifolium pratense* (red clover). These components act as selective estrogen receptor modulators (SERMs) to help balance hormonal fluctuations during the climacteric period. Additionally, the formulation often includes Vitamin D3 and Vitamin K1 to assist in the maintenance of normal bone density and prevent postmenopausal osteoporosis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Morestril (Farmaceutici Damor).